. 2021 Nov 27;15(1):101295. doi: 10.1016/j.tranon.2021.101295

Table 2.

Mechanism of localization of radiopharmaceuticals with risk of nephrotoxicity.

Radiopharmaceuticals	Mechanism of localization
Peptide Receptor Radionuclide Therapy [6] (eg. ¹⁷⁷Lu-DOTATATE, ⁹⁰Y-DOTATOC)	Somatostatin Receptor (SSTR) targeting on cell membrane [21,22]; renal tubular binding (also in glomerulus, vasa recta)
Radioligand therapy [[8], [9], [10],23] (eg. ¹⁷⁷Lu-PSMA, ²²⁵Ac-PSMA)	Prostate Specific membrane antigen (PSMA) targeting on cell membrane; proximal renal tubular binding
Radioimmunotherapy [11] (eg. ⁹⁰Y-Ibritumomab tiuxetan, ¹⁷⁷Lu-Lilotomab satetraxetan)	Targeting of specific cellular antigens (eg. CD20, CD30, CD37); retention of radiolabel in proximal tubular cells